ArticleGeroScience2026
The frailty mortality link in people with chronic diseases pertaining to 13 body organ systems: findings from the UK Biobank study.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Frailty in older adults, particularly those with chronic diseases, has a robust association with risk of mortality, but whether this is the case in middle-aged adults is unclear. We examined the frailty-mortality association in middle-aged adults with chronic diseases and multimorbidity. Data on Fried's frailty phenotype (robust, prefrail, frail) and 47 chronic diseases, mapped to 13 body organ systems, was available on 230,960 participants of the UK Biobank study (mean age 57.8, range 38.0-72.0). The mortality follow-up was 13.3 (± 2.1) years, and associations with mortality were examined using Cox regression, adjusted for socio-demographic factors and health behaviours. Compared to the robust group, frailty (HR, 2.32 (95% confidence intervals, 2.21; 2.43)) and prefrailty (1.35 (1.31; 1.39)) in those with diseases in any body organ system had a higher risk of mortality. Frailty was associated with a higher mortality risk for all 13 groups (all p < 0.01); estimates ranged from 2.25 (2.12; 2.39) for circulatory system diseases to 2.97 (2.60; 3.39) for the eye system. The same was the case for prefrailty; estimates ranged from 1.33 (1.23; 1.43) to 1.61 (1.03; 2.51). Between 19 and 34% of the mortality risk in the 13 disease groups could potentially be explained by frailty/prefrailty. Frailty (p < 0.01) and prefrailty (p < 0.01) had stronger associations with mortality in those with diseases affecting multiple organ systems. These findings highlight the importance of frailty in middle-aged adults with chronic diseases, suggesting that a third of the excess risk of mortality could potentially be addressed by improving frailty status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.